Medical Diagnostics R&D

Showing 388 articles
Business

Glaukos Stock: A Tale of Two Valuations After Recent Rebound

Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.

Business

Heidelberg Materials Gains Momentum as Investors Bet on Green Cement Boom

Heidelberg Materials (XTRA:HEI) is attracting renewed investor interest, fueled by accelerating global demand for sustainable construction materials. The company's strategic positioning in low-carbon cement and aggregates coincides with strong shareholder returns, raising questions about its current valuation in a rapidly evolving market.